Target Identification

Target Validation

Hit Identification

Hit-to-Lead

Lead Optimization

Pre-Clinical Studies

Clinical Studies + Development

INCUBATION PROJECTS
MATURATION PROJECTS
  • New human Tumor-specific antigens in cancer immuno-therapy *
  • Next-generation Chimeric Antigen Receptors (CARs)
  • Synthetic lethality in breast cancer
  • Undisclosed Project 1
 
  • Inhibition of nuclear factor activity in cancer cell proliferation *
  • Novel therapeutic lead in T-cells ALL
  • Inhibition of ERM function in metastatic conditions
  • Novel Kinesin-13 inhibitors
  • Novel MLL-AF9 AML biomarkers & Antibodies *
  • Undisclosed Project 2
 
  • Novel ILK modulators
  • Novel fragments in AML resistance *
  • HDACs as antifungals
  • Human Telomerase Inhibitors
  • Undisclosed Project 4
  • Undisclosed Project 3
  • Plk1-specific inhibitors
  • Inhibition of GPCR in brain tumors *
 
  • Novel PPI modulators *
  • Novel E2 inhibitors *
 
  • Undisclosed Project 5
  • Pharmacological Chaperones *
  • Novel Ras MAPK inhibitors *
 
  • Chemogenomics in AML *
  • Immunotherapy in Leukemia *
 
  • Stem Cell expansion & Transplantation (Small molecules) *
  • Ribavirin in Leukemia
  • Undisclosed Project 6
 
 
Enabling Drug Discovery Tools
  • Engineered Kinases
  • CRISPR/Cas9 chemogenomic profiling
  • BRET Biosensor Program
  • Cyclic peptidomimetics
  • Proprietary Small Molecules (IRIC’s collection)
  • SUMOylation Detection Method

Legend

  *    Project for potential partnership
  IRICoR investment at later stage (Maturation Project Committee)
  IRICoR investment at early stage (Incubation Project Committee)
  IRICoR investment at both early and late stages of development

Last update: 2016-12-05